The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Differential Target MultiplexedTM spinal cord stimulation (SCS) is an established therapy that has shown superior back pain relief to traditional SCS.1 This study evaluates efficacy, device longevity, and recharge requirements of a reduced DTMTM derivative in patients with severe back and leg pain to understand opportunities to tailor therapy based on patient profiles and estimate device longevity and recharge requirements. Subjects were trialed with the DTMTM derivative and those who reported ≥50% improvement in overall pain were eligible for implant. Implanted subjects have reported therapy satisfaction and improved quality of life through 3-months and sustained overall pain relief through 6-months.
Speaker(s):
Celeste
Porritt,
Principal Clinical Research Specialist,
Medtronic
You must be logged in and own this session in order to
post comments.
